Diversified Healthcare Trust
DHC Nasdaq Real Estate Investment Trusts Financials FY2016βFY2025
What Diversified Healthcare Trust does
No business description yet.
- Legal name
- DIVERSIFIED HEALTHCARE TRUST
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 24, 2026
- Accession Β· CIK
- 0001075415-26-000013
0001075415
Revenue and margins
Diversified Healthcare Trust had $1.5B of revenue in fiscal 2025, up 2.8% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β in fiscal 2025, β of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Diversified Healthcare Trust returned $10.8M to shareholders in fiscal 2025. The diluted share count rose 0.3%.
Balance sheet
Cash, debt and the ratios that show how comfortably Diversified Healthcare Trust can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $635M | $658M | $246M | $145M | $105M |
| Debt incl. finance leases | β | β | β | $3.1B | $2.4B |
| Debt / equity | β | β | β | 1.6x | 1.5x |
| Total assets | $6.6B | $6.0B | $5.4B | $5.1B | $4.4B |
| Total liabilities | $4.0B | $3.4B | $3.1B | $3.2B | $2.7B |
| Shareholders' equity | $2.7B | $2.6B | $2.3B | $2.0B | $1.7B |
| Net debt (β = net cash) | β | β | β | $2.9B | $2.3B |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 | β / 6 | β / 6 | β / 6 | β / 6 | β / 6 | β / 6 | 4 / 7 |
| Accruals ratio | β3.9% | β3.7% | β1.5% | β5.1% | β4.5% | 3.6% | 0.4% | β5.3% | β9.1% | β5.6% |
| Altman Z'' | β | β | β | β | β | β | β | β | β | β |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.1B | $1.1B | $1.1B | $1.0B | $1.6B | $1.4B | $1.3B | $1.4B | $1.5B | $1.5B |
| Operating income | $303M | $275M | β | β | β | β | β | β | β | β |
| Interest expense | $168M | $165M | $179M | $180M | $201M | $256M | $209M | $192M | $235M | $204M |
| Pretax income | $142M | $152M | $292M | β$82.8M | β$133M | $181M | β$21.1M | β$273M | β$371M | β$321M |
| Income tax | $0.4M | $0.5M | $0.5M | $0.4M | $1.3M | $1.4M | $0.7M | $0.4M | $0.5M | $1.7M |
| Net income | $141M | $148M | $287M | β$88.2M | β$139M | $175M | β$15.8M | β$294M | β$370M | β$286M |
| Net income to common | $137M | $106M | β | β | β | β | β | β | β | β |
| Diluted EPS | $0.60 | $0.62 | $1.21 | β$0.37 | β$0.59 | $0.73 | β$0.07 | β$1.23 | β$1.55 | β$1.19 |
| Diluted shares | 0.24B | 0.24B | 0.24B | 0.24B | 0.24B | 0.24B | 0.24B | 0.24B | 0.24B | 0.24B |
| Cash flow | ||||||||||
| Cash from operations | $424M | $419M | $393M | $266M | $159M | β$63.3M | β$40.4M | $10.5M | $112M | β$19.6M |
| Depreciation and amortization | $288M | $277M | $286M | $289M | $270M | $271M | $239M | $284M | $285M | $262M |
| Stock-based compensation | $2.2M | $2.2M | $2.2M | $1.4M | $1.6M | $2.0M | $1.7M | $1.8M | $2.7M | $3.4M |
| Share buybacks | $0.5M | $0.3M | $0.4M | $0.3M | $0.2M | $0.4M | $0.2M | $0.4M | $0.9M | $1.1M |
| Dividends paid | $370M | $371M | $371M | $200M | $42.8M | $9.5M | $9.6M | $9.6M | $9.6M | $9.7M |
| Dividends and buybacks | $371M | $371M | $371M | $200M | $43.0M | $9.9M | $9.7M | $10.0M | $10.5M | $10.8M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $31.7M | $31.2M | $55.0M | $37.4M | $74.4M | $635M | $658M | $246M | $145M | $105M |
| Total debt | β | β | $3.7B | β | β | β | β | β | $3.1B | $2.4B |
| Finance lease liabilities | β | β | β | β | $7.8M | $6.6M | $5.3M | $3.9M | $2.3M | $0.6M |
| Intangible assets | $514M | $472M | $419M | $338M | $287M | $48.7M | $45.4M | $33.9M | $26.3M | $20.7M |
| Total assets | $7.2B | $7.3B | $7.2B | $6.7B | $6.5B | $6.6B | $6.0B | $5.4B | $5.1B | $4.4B |
| Total liabilities | $4.0B | $4.0B | $4.0B | $3.8B | $3.9B | $4.0B | $3.4B | $3.1B | $3.2B | $2.7B |
| Shareholders' equity | $3.2B | $3.1B | $3.0B | $2.7B | $2.5B | $2.7B | $2.6B | $2.3B | $2.0B | $1.7B |
| Margins | ||||||||||
| Operating margin | 28.6% | 25.6% | β | β | β | β | β | β | β | β |
| EBITDA margin | 55.9% | 51.4% | β | β | β | β | β | β | β | β |
| Net margin | 13.4% | 13.7% | 25.7% | β8.5% | β8.5% | 12.6% | β1.2% | β20.8% | β24.8% | β18.6% |
| Returns | ||||||||||
| Return on equity | 4.4% | 4.7% | 9.4% | β3.1% | β5.3% | 6.8% | β0.6% | β11.8% | β17.2% | β15.8% |
| Return on assets | 2.0% | 2.0% | 4.0% | β1.3% | β2.1% | 2.7% | β0.2% | β5.1% | β7.0% | β6.0% |
| Return on tangible equity | 5.1% | 4.0% | 11.0% | β3.7% | β6.3% | 6.7% | β0.6% | β12.7% | β19.2% | β17.4% |
| Growth | ||||||||||
| Revenue growth | β | 1.6% | 3.9% | β6.9% | 56.9% | β15.2% | β7.2% | 9.9% | 6.0% | 2.8% |
| Net income growth | β | 4.5% | 94.3% | β130.8% | β | β | β109.0% | β | β | β |
| EPS growth | β | 3.3% | 95.2% | β130.6% | β | β | β109.6% | β | β | β |
| Share count change | β | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 0.1% | 0.2% | 0.3% | 0.3% |
| Financial health | ||||||||||
| Debt / equity | β | β | 1.2x | β | β | β | β | β | 1.6x | 1.5x |
| Interest coverage | 1.8x | 1.7x | β | β | β | β | β | β | β | β |
| Capital allocation | ||||||||||
| Stock comp / revenue | 0.2% | 0.2% | 0.2% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.2% | 0.2% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | β | β | β | β | β | β | β | 4.0 |
| Accruals ratio | β3.9% | β3.7% | β1.5% | β5.1% | β4.5% | 3.6% | 0.4% | β5.3% | β9.1% | β5.6% |
Source: SEC EDGAR XBRL filings (CIK 0001075415). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.